Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. director Muneer A. Satter, through an affiliated investment entity, reported a large open-market purchase of the company’s common stock. On May 28, 2026, Alerce Medical Technology Partners, L.P. bought 613,497 shares at a price of $5.41 per share, with Satter having sole voting and dispositive power over these shares.
After this transaction, entities associated with Satter are shown as holding 10,342,134 shares in total, including 240,000 shares in the Muneer A. Satter Revocable Trust and additional shares in various trusts and partnerships. Satter disclaims beneficial ownership of many of these indirect holdings except to the extent of his pecuniary interest.
Annexon, Inc. ownership disclosure: Reporting Persons led by Biotechnology Value Fund entities report beneficial ownership positions in Annexon common stock as of the close of business on March 31, 2026. The filing lists individual holdings including 4,644,823 shares for BVF, 3,399,850 shares for BVF2 and 522,906 shares for Trading Fund OS.
The filing states an aggregate holding of 8,698,173 shares attributable through related entities and managed accounts, representing approximately 5.4% for certain reporting persons based on 160,474,333 shares outstanding plus 2,027,384 shares issued on March 27, 2026 upon exercise of pre-funded warrants.
Annexon, Inc. director William H. Carson bought 8,000 shares of common stock in an open-market transaction at $5.78 per share. After this purchase, he directly holds 78,405 shares of Annexon stock. The filing notes the transaction was made under his pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Annexon reported first-quarter 2026 results showing a narrower loss and solid liquidity while advancing its late-stage pipeline. Net loss was $44.1 million versus $54.4 million a year earlier, as research and development spending fell to $35.8 million and general and administrative expenses rose modestly to $10.3 million.
Cash, cash equivalents and short-term investments totaled $225.0 million, and management believes this will fund operations into the second half of 2027. The company continues to focus on tanruprubart for Guillain-Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral ANX1502 for autoimmune conditions, while maintaining additional capital access through at-the-market equity programs.
Annexon, Inc. reported first quarter 2026 results and highlighted progress across its late-stage neuroinflammatory pipeline. The company recorded a net loss of $44.1 million, or $0.23 per share, for the quarter ended March 31, 2026, compared with a net loss of $54.4 million, or $0.37 per share, a year earlier.
Research and development expenses were $35.8 million, down from $48.2 million, primarily reflecting spending on the Phase 3 ARCHER II trial of vonaprument in geographic atrophy and regulatory activities for tanruprubart in Guillain-Barré syndrome. General and administrative expenses were $10.3 million, up from $9.2 million, mainly due to consulting and professional services.
Annexon reported cash, cash equivalents and short-term investments of approximately $225 million as of March 31, 2026, and expects this to fund operations and planned milestones into the second half of 2027. Key upcoming catalysts include topline Phase 3 vonaprument data in geographic atrophy in the fourth quarter of 2026, a planned Biologics License Application submission for tanruprubart in Guillain-Barré syndrome in 2026, and proof-of-concept data for oral C1 inhibitor ANX1502 in 2026.
Annexon, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on four key items: electing two Class III directors, ratifying KPMG LLP as auditor for 2026, holding an advisory vote on executive pay, and approving a significant increase in authorized common stock.
The company currently has 300,000,000 authorized common shares and 162,507,278 shares outstanding as of April 13, 2026. It proposes raising authorized common shares to 500,000,000 to support future capital raising, strategic transactions, and equity incentives, noting only 24,753,021 shares remain unissued and unreserved. As of the same date, substantial blocks of shares are reserved for equity plans, warrants, and at-the-market sales programs. The board recommends voting “For” all four proposals.
Annexon, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 11, 2026. The Board asks stockholders to vote on: election of two Class III directors, ratification of KPMG as auditor, an advisory say-on-pay vote, and an amendment to increase authorized common stock from 300,000,000 to 500,000,000 shares. The record date for voting is April 13, 2026 and there were 162,507,278 shares outstanding on that date. The proxy includes disclosure of director nominees, board committees, executive officers, 2025 executive compensation, equity awards and the Board’s recommendation to vote “For” each proposal.
Annexon, Inc. director William H. Carson reported buying additional company stock. On April 10, 2026, he made an open-market purchase of 8,000 shares of common stock at $6.20 per share, bringing his direct holdings to 70,405 shares of Annexon common stock.
The filing notes that this transaction was executed under Carson’s Rule 10b5-1 trading plan, adopted on December 8, 2025, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.
Annexon, Inc. is a clinical-stage biopharma company developing targeted immunotherapies for complement‑mediated neuroinflammatory diseases of the body, brain and eye.
The company’s late-stage programs include tanruprubart for Guillain‑Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral candidate ANX1502 for autoimmune conditions, all built around inhibition of the classical complement pathway, particularly C1q and C1s.
Annexon reports it will need substantial additional financing, has no approved products, and is advancing multiple precision-medicine programs while relying on third‑party manufacturers and extensive patent protection for its platform and pipeline.